Deferasirox Tablet, For Suspension
Product Images NDC 72205-391

View Photos of Packaging, Regulatory Labels, and Product Appearance

Product Visual Gallery

This gallery contains 5 technical images submitted to the FDA as part of the official labeling for Deferasirox (NDC 72205-391). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Novadoz Pharmaceuticals Llc, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Deferasirox-tabs-os-125-mg-30s-cntr-lbl (Deferasirox Tabs Os 125 mg 30s Cntr Lbl)

Deferasirox-tabs-os-125-mg-30s-cntr-lbl (Deferasirox Tabs Os 125 mg 30s Cntr Lbl)
This text is a label of Deferasirox Tablets for Oral Suspension, 125 mg per tablet. The tablets must be dispersed in water, orange, or apple juice before ingestion. It includes dosage instructions, storage conditions, the manufacturer's information, distribution details, and contact information. The Pharmacist should dispense the accompanying Medication Guide to each patient.*
FDA Label Image

Deferasirox-tabs-os-250-mg-30s-cntr-lbl (Deferasirox Tabs Os 250 mg 30s Cntr Lbl)

Deferasirox-tabs-os-250-mg-30s-cntr-lbl (Deferasirox Tabs Os 250 mg 30s Cntr Lbl)
This is a medication guide for Deferasirox Tablets for Oral Suspension with 250 mg per tablet. The tablets should not be chewed or swallowed whole, but instead dispersed in water, orange, or apple juice before ingestion. It is advised to store the tablets at 20°C to 25°C (68°F to 77°F) with excursions permitted to 15°C to 30°C (59°F to 86°F). The medication should be protected from moisture and kept out of the reach of children. Manufactured by MSN Laboratories Private Limited in India and distributed by Novadoz Pharmaceuticals LLC in Piscataway, NJ. For dosage information refer to the prescribing information. Make sure to dispense the accompanying Medication Guide to each patient.*
FDA Label Image

Deferasirox-tabs-os-500-mg-30s-cntr-lbl (Deferasirox Tabs Os 500 mg 30s Cntr Lbl)

Deferasirox-tabs-os-500-mg-30s-cntr-lbl (Deferasirox Tabs Os 500 mg 30s Cntr Lbl)
This is a description of Deferasirox Tablets used for oral suspension, with a dosage of 500 mg per tablet. The tablets should not be chewed or swallowed whole but dispersed in water, orange, or apple juice before ingestion. Each pack contains 30 tablets. The medication guide should be dispensed to each patient by the pharmacist. The tablets should be stored at a temperature between 20°C to 25°C (68°F to 77°F), with excursions permitted to 15°C to 30°C (59°F to 86°F). The product should be protected from moisture and kept out of reach of children. The manufacturer is MSN Laboratories Private Limited in India, and the distributor is Novadoz Pharmaceuticals LLC based in Piscataway, NJ. The issued date is 05/2025.*
FDA Label Image

Deferasirox-tabs-os-figure-1 (Deferasirox Tabs Os Figure 1)

Deferasirox-tabs-os-figure-1 (Deferasirox Tabs Os Figure 1)
This text mentions the change in serum iron content, serum ferritin, and provides information on Deferasirox Tablets Dose in mg/kg/day. It appears to be related to iron levels in the body and possibly the treatment of iron overload.*
FDA Label Image

Deferasirox-tabs-os-structure (Deferasirox Tabs Os Structure)

* These product label images have been analyzed using experimental machine learning. Please verify findings with the primary label text.